Stockscreener 앱 받기
106.68
4.82%
-5.40
시간 외 거래:
106.68
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Has Average Target Price of $134.68 - MarketBeat
Form 4 Kymera Therapeutics Inc For: 1 October By Investing.com - Investing.com Nigeria
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock - Investing.com
Form 4 Kymera Therapeutics Inc For: 1 October By Investing.com - Investing.com India
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock By Investing.com - Investing.com UK
After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares. - Stock Titan
A 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi. - Stock Titan
Kymera Therapeutics (NasdaqGM:KYMR) Stock Forecast & Analyst Predictions - Simply Wall Street
Bank of America Corp DE Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc.Common Stock (Nasdaq:KYMR) Price Chart - The Chronicle-Journal
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Canada
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com India
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Australia
KYMR Upgraded by Wolfe Research -- Rating Raised to Outperform - GuruFocus
Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com South Africa
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com Canada
Fund giant T. Rowe Price holds a double-digit stake in Kymera (KYMR) - Stock Titan
Have Kymera Therapeutics Insiders Been Selling Stock? - simplywall.st
36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc - MarketBeat
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Nigeria
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Australia
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Canada
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com
Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock - MarketBeat
Kymera (NASDAQ: KYMR) insider plans stock sale to cover taxes - Stock Titan
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - The Globe and Mail
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC - MarketBeat
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network
Executive at Kymera Therapeutics (NASDAQ: KYMR) plans another stock sale after June trade of $4.4M - Stock Titan
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - manilatimes.net
Five September events will webcast Kymera live - Stock Titan
Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - investingnews.com
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - marketscreener.com
A clinical trial testing an oral medicine for eczema has finished enrolling patients. Kymera expects topline data by year-end 2026. - Stock Titan
Kymera Therapeutics (NASDAQ:KYMR) Gains on Higher Price Target - Kalkine Media
KYMR Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Given New $170.00 Price Target at Guggenheim - MarketBeat
Guggenheim raises Kymera Therapeutics price target to $170 on STAT6 program - Investing.com Nigeria
Yiheng Capital Management L.P. Sells 10,000 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Alyeska Investment Group L.P. - MarketBeat
4.41%
자본화:
|
볼륨(24시간):